Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

149 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Differential effects of iron chelators on iron burden and long-term morbidity and mortality outcomes in a large cohort of transfusion-dependent β-thalassemia patients who remained on the same monotherapy over 10 years.
Musallam KM, Barella S, Origa R, Ferrero GB, Lisi R, Pasanisi A, Longo F, Gianesin B, Forni GL; Webthal® project. Musallam KM, et al. Among authors: forni gl. Blood Cells Mol Dis. 2024 Jul;107:102859. doi: 10.1016/j.bcmd.2024.102859. Epub 2024 May 29. Blood Cells Mol Dis. 2024. PMID: 38820707
Deferiprone versus deferoxamine in sickle cell disease: results from a 5-year long-term Italian multi-center randomized clinical trial.
Calvaruso G, Vitrano A, Di Maggio R, Ballas S, Steinberg MH, Rigano P, Sacco M, Telfer P, Renda D, Barone R, Maggio A; Investigators of the Multicenter Randomized Clinical Trial of Deferiprone versus Deferoxamine in Sickle-Cell-Disease. Calvaruso G, et al. Blood Cells Mol Dis. 2014 Dec;53(4):265-71. doi: 10.1016/j.bcmd.2014.04.004. Epub 2014 May 9. Blood Cells Mol Dis. 2014. PMID: 24814618 Clinical Trial.
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study.
Gattermann N, Finelli C, Porta MD, Fenaux P, Ganser A, Guerci-Bresler A, Schmid M, Taylor K, Vassilieff D, Habr D, Domokos G, Roubert B, Rose C; EPIC study investigators. Gattermann N, et al. Leuk Res. 2010 Sep;34(9):1143-50. doi: 10.1016/j.leukres.2010.03.009. Epub 2010 May 6. Leuk Res. 2010. PMID: 20451251 Clinical Trial.
Deferiprone and idiosyncrasic neutropenia: light and shadow.
Fioredda F, Forni GL. Fioredda F, et al. Among authors: forni gl. Blood Adv. 2024 Nov 12;8(21):5651-5652. doi: 10.1182/bloodadvances.2024013479. Blood Adv. 2024. PMID: 39476036 Free PMC article. No abstract available.
Mortality, Clinical Complications, and Healthcare Resource Utilization Associated with Managing Transfusion-Dependent β-Thalassemia and Sickle Cell Disease with Recurrent Vaso-occlusive Crises in Italy.
Udeze C, Dovizio M, Veronesi C, Esposti LD, Li N, Dang TXMP, Forni GL. Udeze C, et al. Among authors: forni gl. Pharmacoecon Open. 2024 Oct 28. doi: 10.1007/s41669-024-00532-4. Online ahead of print. Pharmacoecon Open. 2024. PMID: 39468000 Free article.
Safety and efficacy of ketorolac continuous infusion for multimodal analgesia of vaso-occlusive crisis in patients with sickle cell disease.
Pinto VM, Gianesin B, Sardo S, Mazzi F, Baiardi G, Menotti S, Piras F, Quintino S, Robello G, Mattioli F, Finco G, Forni GL, De Franceschi L. Pinto VM, et al. Among authors: forni gl. Orphanet J Rare Dis. 2024 Jan 22;19(1):22. doi: 10.1186/s13023-023-02998-7. Orphanet J Rare Dis. 2024. PMID: 38254184 Free PMC article.
'Phenoconversion' in adult patients with β-thalassemia.
Musallam KM, Barella S, Origa R, Ferrero GB, Lisi R, Pasanisi A, Longo F, Gianesin B, Forni GL; Webthal® project. Musallam KM, et al. Among authors: forni gl. Am J Hematol. 2024 Mar;99(3):490-493. doi: 10.1002/ajh.27194. Epub 2024 Jan 2. Am J Hematol. 2024. PMID: 38165006
149 results